Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Cardiology

Treatment Options for SQT2

At a Glance

Treatment for short QT syndrome type 2 is individualized because the condition is rare. An ICD may protect people with a history of cardiac arrest or dangerous rhythms, while quinidine or hydroquinidine may be considered with close ECG, blood-test, and medication-interaction monitoring.

Managing Short QT Syndrome Type 2 (SQT2) requires a careful balance between protecting you from heart rhythm events and minimizing the burdens of medical treatment. Because SQT2 is so rare, treatment evidence is largely from expert consensus, case reports, and small observational series. Instead of a single predetermined standard, your care team will likely discuss two main treatment options: an Implantable Cardioverter-Defibrillator (ICD) and medication, primarily quinidine or hydroquinidine [1][2].

The Role of the ICD

An Implantable Cardioverter-Defibrillator (ICD) is a small device placed under the skin that monitors your heart rhythm 24/7. If it detects a life-threatening, fast rhythm, it can deliver an electrical shock to reset the heart [3].

  • Secondary Prevention: If you have already survived a cardiac arrest or had a documented life-threatening arrhythmia, an ICD is considered established for secondary prevention [1][4].
  • Primary Prevention: If you have the diagnosis but have never had a major event, the decision is more complex. While an ICD can be lifesaving, it is not always recommended for everyone because primary-prevention benefit is controversial and not established by solid data [1][5].

Challenges and Risks of ICDs in SQTS

While an ICD provides a safety net, it also comes with specific challenges for people with Short QT Syndrome.

  • T-wave Oversensing: On an ECG, people with SQTS often have tall, peaked T-waves. The ICD may mistake these tall T-waves for a second heartbeat. If the device “double-counts” in this way, it may incorrectly think your heart is beating twice as fast as it actually is, leading to an inappropriate shock [6][7].
  • Complication Rates: In a pooled series of SQTS patients, up to 54% experienced some form of device complication over several years, including inappropriate shocks, lead problems, or infections [6].
  • Device Choice: To reduce some lead-related risks, your doctor may suggest a subcutaneous ICD (S-ICD) or perform specific testing during the procedure [8][7]. However, an S-ICD cannot provide routine bradycardia pacing or antitachycardia pacing (ATP). This is particularly important because SQT2 is associated with slow heart rates; device selection must depend on pacing needs, arrhythmia type, age, anatomy, and sensing results [8].

Pharmacological Treatment: Quinidine

For many years, researchers have searched for a drug that can safely “stretch out” the shortened QT interval in SQTS. Currently, quinidine (or its variant, hydroquinidine) is an individualized, specialist-managed option with limited observational evidence [9].

  • How it Works: Quinidine works by blocking certain potassium channels, which slows down the “recharge” phase of the heart cells. In several small observational groups of SQTS patients, hydroquinidine lengthened the QTc interval from an average of 313 ms to a more normal 380 ms [9][2].
  • Arrhythmia Reduction: Observational studies have reported fewer ventricular tachyarrhythmias after hydroquinidine [2]. However, QTc normalization and fewer events in observational comparisons do not definitively prove prevention of sudden death, and it is generally considered when an ICD is unsuitable, declined, or insufficient [10].

The Burdens and Safety Monitoring of Quinidine

While quinidine is an option, it requires careful management and close monitoring.

  1. Gastrointestinal (GI) Intolerance: The most common reason people stop taking quinidine is stomach upset, including diarrhea, nausea, or cramping. In some series, a large portion of patients discontinued treatment for GI intolerance or poor compliance [2][9].
  2. Risk of Proarrhythmia: Ironically, a drug used to treat arrhythmias can sometimes cause them if the QT interval is stretched too far. This can lead to a specific type of fast rhythm called Torsades de Pointes [11]. Women more often discontinue for QT prolongation [12].
  3. Drug Interactions: Quinidine interacts with many other common medications, including antidepressants (like fluoxetine), antibiotics (macrolides), and other antiarrhythmic drugs. These interactions can dangerously add QT-prolonging effects or alter levels [13][11].
  4. Rare Toxicities: Though rare, quinidine can occasionally affect your liver or your blood’s ability to clot (low platelets) [14][2].

Actionable Safety Warning:
You should not start, stop, or combine medicines without specialist review. Clinicians will need to monitor your QT, electrolytes, renal/hepatic status, and blood counts. Seek urgent care for fainting, sustained palpitations, severe dizziness, or suspected proarrhythmia.

Common questions in this guide

What treatments are used for short QT syndrome type 2?
Treatment is individualized because SQT2 is rare and evidence is limited. The main options discussed are an implantable cardioverter-defibrillator (ICD) to treat life-threatening rhythms and quinidine or hydroquinidine to lengthen the QT interval and reduce abnormal rhythms.
Does everyone with SQT2 need an ICD?
No. An ICD is generally an established option for secondary prevention after a cardiac arrest or documented life-threatening arrhythmia, but its use before any major event is more uncertain. Your specialist will weigh your arrhythmia history, risk profile, device complications, and pacing needs.
What ICD problems are important in SQT2?
Tall T-waves can be misread by an ICD as extra heartbeats, causing an inappropriate shock. Other possible problems include lead complications and infection. A subcutaneous ICD may reduce some lead-related concerns, but it cannot provide routine slow-heart-rate pacing or antitachycardia pacing.
How is quinidine monitored in SQT2?
Quinidine requires specialist supervision with follow-up ECGs to check the QT interval. Clinicians may also monitor electrolytes, kidney and liver function, and blood counts, and review all medicines and supplements for interactions. Do not start, stop, or combine medicines without medical review.
What are common side effects and risks of quinidine?
Stomach problems such as diarrhea, nausea, and cramping are common reasons people stop quinidine. If the QT interval becomes too long, quinidine can cause a dangerous rhythm called torsades de pointes; it can also interact with many medicines and rarely affect the liver or blood-clotting cells. Seek urgent care for fainting, sustained palpitations, or severe dizziness.

Get notified when new evidence is published on short QT syndrome type 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Diagnosis and management of short QT syndrome.

    Bjerregaard P

    Heart rhythm 2018; (15(8)):1261-1267 doi:10.1016/j.hrthm.2018.02.034.

    PMID: 29501667
  2. 2

    Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome.

    Mazzanti A, Maragna R, Vacanti G, et al.

    Journal of the American College of Cardiology 2017; (70(24)):3010-3015 doi:10.1016/j.jacc.2017.10.025.

    PMID: 29241489
  3. 3

    Short QT syndrome: The current evidences of diagnosis and management.

    Dewi IP, Dharmadjati BB

    Journal of arrhythmia 2020; (36(6)):962-966 doi:10.1002/joa3.12439.

    PMID: 33335610
  4. 4

    Cardiac Channelopathies in the Pediatric Patient: Short QT Syndrome.

    Tan RB, Shah MJ

    Cardiac electrophysiology clinics 2025; (17(4)):645-650 doi:10.1016/j.ccep.2025.07.012.

    PMID: 41206177
  5. 5

    Differences in Short QT Syndrome Subtypes: A Systematic Literature Review and Pooled Analysis.

    Raschwitz LS, El-Battrawy I, Schlentrich K, et al.

    Frontiers in genetics 2019; (10()):1312 doi:10.3389/fgene.2019.01312.

    PMID: 32010184
  6. 6

    Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome.

    El-Battrawy I, Besler J, Ansari U, et al.

    Clinical research in cardiology : official journal of the German Cardiac Society 2019; (108(10)):1140-1146 doi:10.1007/s00392-019-01449-3.

    PMID: 30879093
  7. 7

    Implantable cardioverter defibrillator replacement guided by T wave safety margin in a short QT syndrome patient.

    Shen Y, Pan W, Jiang C, et al.

    Pacing and clinical electrophysiology : PACE 2019; (42(5)):557-559 doi:10.1111/pace.13580.

    PMID: 30548872
  8. 8

    Successful extravascular implantable cardioverter-defibrillator implantation in a patient with short QT syndrome: A case report.

    Kodera N, Nishii N, Ueoka A, et al.

    Journal of cardiology cases 2026; (34(4)):139-143 doi:10.1016/j.jccase.2026.06.002.

    PMID: 42889605
  9. 9

    Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome.

    El-Battrawy I, Besler J, Li X, et al.

    Frontiers in pharmacology 2019; (10()):771 doi:10.3389/fphar.2019.00771.

    PMID: 31427960
  10. 10

    [Long and short QT syndromes : Emergency treatment and secondary prophylaxis].

    Horn N, Rüb N, Wolpert C

    Herzschrittmachertherapie & Elektrophysiologie 2020; (31(1)):48-54 doi:10.1007/s00399-020-00666-y.

    PMID: 32025785
  11. 11

    Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.

    Tisdale JE

    Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC 2016; (149(3)):139-52 doi:10.1177/1715163516641136.

    PMID: 27212965
  12. 12

    Influence of Gender on the Tolerability, Safety, and Efficacy of Quinidine Used for Treatment of Supraventricular and Ventricular Arrhythmias.

    Higgins AY, Waks JW, Josephson ME

    The American journal of cardiology 2015; (116(12)):1845-51.

    PMID: 26514302
  13. 13

    Drug Interactions Affecting Antiarrhythmic Drug Use.

    Mar PL, Horbal P, Chung MK, et al.

    Circulation. Arrhythmia and electrophysiology 2022; (15(5)):e007955 doi:10.1161/CIRCEP.121.007955.

    PMID: 35491871
  14. 14

    Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease.

    Deshmukh A, Larson J, Ghannam M, et al.

    Journal of cardiovascular electrophysiology 2021; (32(12)):3173-3178 doi:10.1111/jce.15260.

    PMID: 34586686

This page is for informational purposes only and does not constitute medical advice. Your cardiologist or cardiac electrophysiology team should guide decisions about an ICD, quinidine, monitoring, and urgent symptoms.